Interpretation of WHO consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities-HIV

doi:10.19982/j.issn.1000-6621.20240225

Abstract

Abstract:

In April 2024, the World Health Organization (WHO) published the WHO consolidated guidelines on tuberculosis: Module 6: tuberculosis and comorbidities-HIV contained specific recommendations on screening, diagnosis, treatment, care, and prevention of HIV-associated tuberculosis. These recommendations aim to reduce the disease burden, morbidity, and mortality among patients with both tuberculosis and HIV. The author interprets the key content of this guideline for reference.

Key words: Tuberculosis, HIV, Consensus development conferences as topic

CLC Number:

R52
R512.91

Li Zhili, Liu Yuhong. Interpretation of WHO consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities-HIV[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 869-873. doi: 10.19982/j.issn.1000-6621.20240225

References 14

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1): 15-19. doi:10.19983/j.issn.2096-8493.2024006.
[2]	World Health Organization. Framework for collaborative action on tuberculosis and comorbidities. Geneva: World Health Organization, 2022.
[3]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities. Geneva: World Health Organization, 2024.
[4]	World Health Organization. WHO operational handbook on tuberculosis. Module 6: tuberculosis and comorbidities, second edition. Geneva: World Health Organization, 2024.
[5]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis-rapid diagnostics for tuberculosis detection. Geneva: World Health Organization, 2021.
[6]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2: screening-systematic screening for tuberculosis disease. Geneva: World Health Organization, 2021.
[7]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention-tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[8]	World Health Organization. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization, 2012.
[9]	World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva: World Health Organization, 2004.
[10]	中华医学会感染病学分会艾滋病丙型肝炎学组. 中国艾滋病诊疗指南(2018版). 协和医学杂志, 2019, 10(1):31-52. doi:10.3969/j.issn.1674-9081.2019.01.006.
[11]	中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版). 协和医学杂志, 2022, 13(2):203-226. doi:10.12290/xhyxzz.2022-0097.
[12]	中华医学会感染病学分会艾滋病学组. 艾滋病诊疗指南(第三版). 中华传染病杂志, 2015, 33(10):577-593. doi:10.3760/cma.j.issn.1000-6680.2015.10.001.
[13]	中华医学会感染病学分会艾滋病学组. 艾滋病诊疗指南(2011版). 中华临床感染病杂志, 2011, 4(6):321-330. doi:10.3760/cma.j.issn.1674-2397.2011.06.001.
[14]	中华医学会感染病学分会艾滋病学组制订. 艾滋病诊疗指南. 中华传染病杂志, 2006, 24(2):133-144.

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397.
[2]	Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407.
[3]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[4]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[5]	Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[8]	Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453.
[9]	Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459.
[10]	Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470.
[11]	Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476.
[12]	Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
[13]	Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497.
[14]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[15]	Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512.